SALT
LAKE CITY, Oct. 16, 2023 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"),
a molecular diagnostics company with a unique, patented platform
for the development of molecular diagnostic tests, announced today
that the Company will be hosting a booth this week at Africa
Health/Medlab Africa in Johannesburg,
South Africa on October 17-19,
2023.
The conference is described as the largest gathering of
healthcare companies, technology, products and services in the
sub-Saharan region, catering to an audience of professionals from
the South African Development Community region and around the
world, including distributors, government representatives,
laboratory executives, and purchasing/procurement managers, who
attend to meet with world-class suppliers and manufacturers.
Co-Dx believes that the trade show will contribute valuable
insight into markets that are anticipated to play an important role
in the Company's future as it prepares to launch its upcoming Co-Dx
PCR Home™ platform.
In addition to a test for COVID-19, which is currently
undergoing clinical evaluations on the platform in preparation for
a submission to the FDA, Co-Dx has several other infectious disease
tests in varying stages of development. One of these tests is for
tuberculosis (TB), a disease for which the World Health
Organization estimates 25% of new cases and deaths globally are
found in the African region. Nigeria and South
Africa are two of the 7 countries which have been estimated
to account for over two thirds of global TB cases.
Co-Dx recently announced that it had received funding support
from the Bill & Melinda Gates Foundation to be used towards
completion of the TB test on the new Co-Dx PCR Home platform.
More information about the conference can be found here.
Attendees interested in learning more about the Company are invited
to visit Booth #2.C13.
The Co-Dx PCR Home platform is subject to FDA review and is
not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR Home™ platform and to locate genetic
markers for use in applications other than infectious disease.
Forward-Looking Statements:
This press
release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA) that are subject to a number of risks and uncertainties.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release include statements regarding our belief that our new
platform will help support the worldwide effort to help prevent the
spread of both TB and HPV and our believe that our new platform has
the potential to dramatically improve access to diagnostics and
reduce healthcare costs. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. There can
be no assurance that any of the anticipated results will occur on a
timely basis or at all due to certain risks and uncertainties, a
discussion of which can be found in our Risk Factors disclosure in
our Annual Report on Form 10-K, filed with the Securities and
Exchange Commission (SEC) on March 16,
2023, and in our other filings with the SEC. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-medlab-africa-2023-in-johannesburg-south-africa-301957262.html
SOURCE Co-Diagnostics